Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis

被引:37
作者
McHugh, L
Hu, S
Lee, BK
Santora, K
Kennedy, PE
Berger, EA
Pastan, I
Hamer, DH
机构
[1] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA
[2] NCI, Biochem Lab, Bethesda, MD 20892 USA
[3] NCI, Mol Biol Lab, Bethesda, MD 20892 USA
关键词
D O I
10.1074/jbc.M205456200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HIV-infected cells are selectively killed by an immunotoxin in which a truncated form of Pseudomonas exotoxin A is joined to the variable region of a broadly neutralizing antibody (3B3) that recognizes the viral envelope glycoprotein (Env). To improve the efficacy of this molecule, we used three-dimensional structural information and phage selection data to design 23 single and multiple point mutations in the antibody variable region sequences that contact Env. Substituting an aromatic residue for an aspartate in the third complementarity-determining region of V-H increased the potency of the immunotoxin by similar to10-fold in a cell-killing assay. Detailed analysis of one such mutant, N31H/Q100eY, revealed both a higher affinity for monomeric and cell surface Env and an increased stability against aggregation compared with the starting immunotoxin. Conversion to a disulfide-linked two-chain format further stabilized the protein. N31H/Q100eY retained the ability to bind to Env from multiple viral isolates, to inhibit Env-mediated cell fusion, and to limit spreading viral infection in peripheral blood mononuclear cells. Such site-directed mutants may increase the utility of immunotoxins for reducing or eradicating persistent HIV-1 infection in humans.
引用
收藏
页码:34383 / 34390
页数:8
相关论文
共 26 条
[1]   ELIMINATION OF INFECTIOUS HUMAN-IMMUNODEFICIENCY-VIRUS FROM HUMAN T-CELL CULTURES BY SYNERGISTIC ACTION OF CD4-PSEUDOMONAS EXOTOXIN AND REVERSE-TRANSCRIPTASE INHIBITORS [J].
ASHORN, P ;
MOSS, B ;
WEINSTEIN, JN ;
CHAUDHARY, VK ;
FITZGERALD, DJ ;
PASTAN, I ;
BERGER, EA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (22) :8889-8893
[2]   ANTI-HIV ACTIVITY OF CD4-PSEUDOMONAS EXOTOXIN ON INFECTED PRIMARY HUMAN-LYMPHOCYTES AND MONOCYTE MACROPHAGES [J].
ASHORN, P ;
ENGLUND, G ;
MARTIN, MA ;
MOSS, B ;
BERGER, EA .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (04) :703-709
[3]   IN-VITRO EVOLUTION OF A NEUTRALIZING HUMAN-ANTIBODY TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TO ENHANCE AFFINITY AND BROADEN STRAIN CROSS-REACTIVITY [J].
BARBAS, CF ;
HU, D ;
DUNLOP, N ;
SAWYER, L ;
CABABA, D ;
HENDRY, RM ;
NARA, PL ;
BURTON, DR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :3809-3813
[4]   Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein [J].
Bera, TK ;
Kennedy, PE ;
Berger, EA ;
Barbas, CF ;
Pastan, I .
MOLECULAR MEDICINE, 1998, 4 (06) :384-391
[5]   Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART [J].
Berger, EA ;
Moss, B ;
Pastan, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :11511-11513
[6]   The challenge of viral reservoirs in HIV-1 infection [J].
Blankson, JN ;
Persaud, D ;
Siliciano, RF .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :557-593
[7]   Recombinant immunotoxins for cancer therapy [J].
Brinkmann, U ;
Keppler-Hafkemeyer, A ;
Hafkemeyer, P .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (04) :693-702
[8]   EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY [J].
BURTON, DR ;
PYATI, J ;
KODURI, R ;
SHARP, SJ ;
THORNTON, GB ;
PARREN, PWHI ;
SAWYER, LSW ;
HENDRY, RM ;
DUNLOP, N ;
NARA, PL ;
LAMACCHIA, M ;
GARRATTY, E ;
STIEHM, ER ;
BRYSON, YJ ;
CAO, YZ ;
MOORE, JP ;
HO, DD ;
BARBAS, CF .
SCIENCE, 1994, 266 (5187) :1024-1027
[9]   A LARGE ARRAY OF HUMAN MONOCLONAL-ANTIBODIES TO TYPE-1 HUMAN-IMMUNODEFICIENCY-VIRUS FROM COMBINATORIAL LIBRARIES OF ASYMPTOMATIC SEROPOSITIVE INDIVIDUALS [J].
BURTON, DR ;
BARBAS, CF ;
PERSSON, MAA ;
KOENIG, S ;
CHANOCK, RM ;
LERNER, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :10134-10137
[10]   Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities [J].
Butera, ST .
ANTIVIRAL RESEARCH, 2000, 48 (03) :143-176